Charles Schwab Investment Management Inc. Raises Stock Position in Catalent, Inc. (NYSE:CTLT)

Charles Schwab Investment Management Inc. grew its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 1.1% during the third quarter, Holdings Channel reports. The firm owned 1,656,506 shares of the company’s stock after purchasing an additional 17,681 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Catalent were worth $100,335,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalent during the second quarter worth about $42,000. Sentry Investment Management LLC acquired a new position in shares of Catalent during the third quarter worth about $53,000. Longfellow Investment Management Co. LLC grew its position in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new position in shares of Catalent during the third quarter worth about $73,000.

Insider Buying and Selling at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by insiders.

Catalent Stock Performance

Shares of CTLT opened at $60.76 on Wednesday. The stock has a 50 day moving average price of $59.83 and a 200 day moving average price of $58.36. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $11.03 billion, a price-to-earnings ratio of -26.88, a price-to-earnings-growth ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a 52-week low of $36.74 and a 52-week high of $61.50.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the firm posted ($0.10) EPS. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. Research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the subject of a number of analyst reports. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat, Catalent has an average rating of “Hold” and a consensus price target of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.